Adamas Pharmaceuticals Stock News

Adamas One Corp. JEWL, said it priced 2.45 million shares at $4.50 a share for proceeds of $11 million in its initial public offering for trading on Friday on the Nasdaq. The Scottsdale, Ariz.

Squarepoint Ops LLC decreased its stake in Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) by 69.5% during the second quarter, Holdings Channel.com reports. The institutional investor owned 17,561 shares of the specialty pharmaceutical companys stock after selling 39,923 shares during the quarter. Squarepoint Ops LLCs holdings in Adamas Pharmaceuticals were worth $93,000 at the end of the most []

ROCKVILLE, Md., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Supernus proposed acquisition of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) expired at 11:59 p.m. on November 22, 2021.

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) was the target of a significant drop in short interest in October. As of October 29th, there was short interest totalling 881,300 shares, a drop of 44.9% from the October 14th total of 1,600,000 shares. Based on an average daily volume of 1,130,000 shares, the short-interest ratio is currently 0.8 days. []

Northland Securities lowered shares of Adamas Pharmaceuticals (NASDAQ:ADMS) from an outperform rating to a market perform rating in a research report released on Wednesday, The Fly reports. ADMS has been the topic of several other research reports. Piper Sandler lowered Adamas Pharmaceuticals from an overweight rating to a neutral rating and boosted their price target []

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Equities researchers at Piper Sandler cut their Q3 2021 earnings per share (EPS) estimates for Adamas Pharmaceuticals in a report issued on Wednesday, November 10th. Piper Sandler analyst D. Amsellem now forecasts that the specialty pharmaceutical company will post earnings of ($0.43) per share for the quarter, down from their []

Equities analysts expect that Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) will report $28.55 million in sales for the current quarter, according to Zacks. Five analysts have issued estimates for Adamas Pharmaceuticals earnings, with estimates ranging from $25.75 million to $30.80 million. Adamas Pharmaceuticals reported sales of $21.01 million in the same quarter last year, which would suggest []

NEW YORK, Oct. 15, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Ac

New York, New York--(Newsfile Corp. - October 11, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Adamas Pharmaceuticals, Inc. (NASDA

MILWAUKEE, Oct. 11, 2021 /PRNewswire/ -- Ademi LLP is investigating Adamas (Nasdaq: ADMS), for possible breaches of fiduciary duty and other violations of law in its transaction with Supernus. Click

ADMS stock is seeing huge gains this morning as it announces a planned merger with fellow biopharma company Supernus worth $400 million. The post ADMS Stock Soars 70% Thanks to Adamas Pharmaceuticals

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) to Supernus Pharmaceuticals, Inc. for $

Supernus Pharmaceuticals Inc (NASDAQ: SUPN) has agreed to acquire Adamas Pharmaceuticals Inc (NASDAQ: ADMS) for $9.10 per share, or $450 million. The deal consideration includes $8.10 per share in

The stock price of Adamas Pharmaceuticals Inc (NASDAQ: ADMS) increased by over 70% pre-market today. This is why it happened.